Search Within

Martin Stuart Tallman

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (57)
  2. Journal Article (52)
  3. Research Letter (3)
  4. Correspondence (1)
Groups
  1. Adult Leukemia (113)
  2. Center for Hematologic Malignancies (113)
  3. Department of Medicine (113)
  4. Epidemiology and Biostatistics (113)
  5. Hematologic Malignancies, Division of (113)
  6. Biostatistics Service (105)

More Groups

People
  1. Sean Devlin (65)
  2. Ross Levine (55)
  3. Eytan Stein (39)
  4. Christopher Famulare (26)
  5. Jae Park (26)
  6. Aaron Goldberg (24)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (5)
  4. 2022 (7)
  5. 2021 (9)
  6. 2020 (12)

More Years

Publications
  1. Blood (52)
  2. Leukemia Research (11)
  3. Haematologica (7)
  4. American Journal of Hematology (4)
  5. Biology of Blood and Marrow Transplantation (4)
  6. Blood Advances (4)

More Publications

Publishers
  1. American Society of Hematology (56)
  2. Elsevier Ltd (11)
  3. Nature Publishing Group (8)
  4. Ferrata Storti Foundation (7)
  5. Elsevier Inc. (6)
  6. American Association for Cancer Research (4)

More Publishers

Results (113)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program
    Journal Article

    Park, S. M.; Gönen, M.; Vu, L.; Minuesa, G.; Tivnan, P.; Barlowe, T. S.; Taggart, J.; Lu, Y.; Deering, R. P.; Hacohen, N.; more...
    Journal of Clinical Investigation (2015)

    Fulltext@MSK | Save
  • Telomere length is associated with specific mutations and mutation classes in patients with acute myeloid leukemia
    Meeting Abstract

    Watts, J. M.; Dumitriu, B.; Hilden, P.; Chen, C.; Rapaport, F.; Kishtagari, A.; Ahn, J.; Devlin, S. M.; Rampal, R. K.; Levine, R. L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia
    Meeting Abstract

    Walter, R. B.; Othus, M.; Paietta, E. M.; Racevskis, J.; Fernandez, H. F.; Lee, J. W.; Sun, Z. X.; Tallman, M. S.; Patel, J. P.; Gonen, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia
    Meeting Abstract

    Seddon, A. N.; Michael, A. G.; Adel, N. G.; Tallman, M. S.; Akin, O.; Chaim, J.; Drill, E.
    Blood (2014)

    Fulltext@MSK | Save
  • Msi2 maintains the MLL leukemia stem cell regulatory program
    Meeting Abstract

    Park, S. M.; Gonen, M.; Vu, L. P.; Minuesa, G.; Tivnan, P.; Barlowe, T.; Taggart, J.; Lu, Y. H.; Deering, R. P.; Hacohen, N.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era
    Meeting Abstract

    Mantha, S.; Goldman, D.; Devlin, S. M.; Lee, J. W.; Zannino, D.; Douer, D.; Iland, H. J.; Litzow, M. R.; Stein, E. M.; Appelbaum, F.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Genomic analysis of serial samples from CLL patients identifies clonal events associated with disease progression
    Meeting Abstract

    Gardner, J. R.; Nahas, M.; He, J.; Aumann, S.; Gonen, M.; Patel, M.; Knapp, K. M.; Palomba, M. L.; Yelensky, R.; Donahue, A. L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Minimal residual disease assessment by flow cytometry in AML is an independant prognostic factor even after adjusting for cytogenetic/molecular abnormalities
    Meeting Abstract

    Ganzel, C.; Sun, Z. X.; Gonen, M.; Patel, J. P.; Abdel-Wahab, O.; Fernandez, H. F.; Rowe, J. M.; Tallman, M. S.; Levine, R. L.; Paietta, E. M.
    Blood (2014)

    Fulltext@MSK | Save
  • Secondary ALL may be independent of prior cytotoxic therapy
    Meeting Abstract

    Ganzel, C.; Devlin, S. M.; Douer, D.; Stein, E. M.; Rowe, J. M.; Tallman, M. S.
    Blood (2014)

    Fulltext@MSK | Save
  • The addition of radiation therapy to initial treatment for extramedullary acute myeloid leukemia does not offer a survival benefit when added to chemotherapy
    Meeting Abstract

    Feller, F. M.; Patel, M.; Devlin, S. M.; Maloy, M.; Tallman, M. S.; Perales, M. A.; Rampal, R. K.
    Blood (2014)

    Fulltext@MSK | Save